Document:

Ex. 10.01

Exhibit 10.01

THIRD EXTENSION AND AMENDMENT TO 
QUARTZ SAND PRODUCTS PURCHASE AGREEMENT
    
This Third Extension and Amendment to Quartz Sand Products Purchase Agreement, effective as of June 30, 2012 (the “Third Extension and Amendment”), by and between Unimin Corporation (“Seller”) and Momentive Performance Materials Quartz, Inc. (formerly known as GE Quartz, Inc.) (“Buyer”).  Defined terms used herein and not otherwise defined herein shall have the meanings given such terms in the “Agreement” (as defined herein below). 

WHEREAS, Seller and Buyer are parties to a certain Quartz Sand Products Purchase Agreement, effective as of February 15, 2005, as amended, including but not limited to by that certain (i) Extension and Amendment to Quartz Sand Products Purchase Agreement effective as of December 31, 2010 and (ii) Second Extension and Amendment to Quartz Sand Products Purchase Agreement effective as of December 31, 2011 (the “Second Extension”) (together, the “Agreement”); and

WHEREAS, Seller and Buyer wish to amend the Agreement to provide for an extension of the term thereof;

NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the Seller and Buyer do hereby agree that the Agreement is amended as follows:

1.    The Extension Term is extended through September 30, 2012.

2.    Notwithstanding anything in the Agreement to the contrary, during the period from June 30, 2012 through September 30, 2012, the prices for the products set forth in the Second Extension shall be as provided in the Second Extension.

3.    The Agreement, as amended hereby, remains in full force and effect and is hereby ratified and affirmed.  

IN WITNESS WHEREOF, the parties have caused this Third Extension and Amendment to be duly executed effective as of the date first written above.

	
				
	MOMENTIVE PERFORMANCE MATERIALS        
QUARTZ, INC.
	 
	UNIMIN CORPORATION
	 

	 
	 
	 
	 

	By: Authorized Person    
	 
	By: Authorized Person    
	 

	 
	 
	 
	 

	Name: Authorized Person    
	 
	Name: Authorized Person    
	 

	 
	 
	 
	 

	Date: 7/17/12
	 
	Date: 7/16/12mdce_ex1036.htm

EXHIBIT 10.36

 

Medical Care Technologies Inc.

Room 815, No. 2 Building Beixiaojie, Dongzhimen Nei, Beijing, People's Republic of China Website: 

www.medicaretechinc.com   Tel: (8610) 6407 0580

 

	 	May 29, 2012

 

Manhattan Transfer Registrar Co. 57 Eastwood Road Miller Place, NY 11764

 

Ladies and Gentlemen:

 

MEDICAL CARE TECHNOLOGIES INC., a Nevada corporation (the "Company") and Nicholas J. Morano, LLC (the "Investor") have entered into an Amended and Restated 10% Convertible Debenture dated as of May 29, 2012, in the principal amount of $65,000.00 (the "Note").

 

A copy of the Note is attached hereto. You should familiarize yourself with your issuance and delivery obligations, as Transfer Agent, contained therein. The shares to be issued are to be registered in the names of the registered holder of the securities submitted for conversion or exercise.

 

You are hereby irrevocably authorized and instructed to reserve a sufficient number of shares of common stock ("Common Stock") of the Company (initially, 200,000,000 shares) for issuance upon full conversion of the Note in accordance with the terms thereof. The amount of Common Stock so reserved may be increased, from time to time, by written instructions of the Company and the Investor.

 

The ability to convert the Note in a timely manner is a material obligation of the Company pursuant to the Note. Your firm is hereby irrevocably authorized and instructed to issue shares of Common Stock of the Company (without any restrictive legend) to the Investor

(A) upon your receipt from the Investor of: (i) a notice of conversion ("Conversion Notice") executed by the Investor; and (ii) an opinion of counsel of the Investor, in form, substance and scope customary for opinions of counsel in comparable transactions (and satisfactory to the transfer agent), to the effect that the shares of Common Stock of the Company issued to the Investor pursuant to the Conversion Notice are not "restricted securities" as defined in Rule 144 and should be issued to the Investor without any restrictive legend; and (B) the number of shares to be issued is less than 4.99% of the total issued common stock of the Company.

 

The Company hereby requests that your firm act immediately and without delay with respect to the issuance of Common Stock pursuant to any Conversion Notices received from the Investor.

 

The Company shall indemnify you and your officers, directors, principals, partners, agents and representatives, and hold each of them harmless from and against any and all loss, liability, damage, claim or expense (including the reasonable fees and disbursements of its attorneys) incurred by or asserted against you or any of them arising out of or in connection the instructions set forth herein, the performance of your duties hereunder and otherwise in respect hereof, including the costs and expenses of defending yourself or themselves against any claim or liability hereunder, except that the Company shall not be liable hereunder
as to matters in respect of which it is determined that you have acted with gross negligence or in bad faith. You shall have no liability to the Company in respect to any action taken or any failure to act in respect of this if such action was taken or omitted to be taken in good faith, and you shall be entitled to rely in this regard on the advice of counsel.

 

  

1

  

 

The Board of Directors of the Company has approved the foregoing (irrevocable instructions) and does hereby extend the Company's irrevocable agreement to indemnify your firm for all loss, liability or expense in carrying out the authority and direction herein contained on the terms herein set forth.

 

The Company agrees that in the event that the Transfer Agent resigns as the Company's transfer agent, the Company shall engage a suitable replacement transfer agent that will agree to serve as transfer agent for the Company and be bound by the terms and conditions of these Irrevocable Instructions within five (5) business days.

 

The Investor is intended to be and are third party beneficiaries hereof, and no amendment or modification to the instructions set forth herein may be made without the consent of the Investor.

 

Very truly yours.

 

MEDICAL CARE TECHNOLOGIES INC.

 

 

  

2

  

 

Medical Care Technologies Inc. 

Room 815, No. 2 Building Beixiaojie, Dongzhimen Nei, Beijing, People's Republic of China 

Website: www.medicaretechinc.com   Tel: (8610) 6407 0580

	 	May 29, 2012

 

Manhattan Transfer Registrar Co. 57 Eastwood Road Miller Place, NY 11764

 

Ladies and Gentlemen:

 

MEDICAL CARE TECHNOLOGIES INC., a Nevada corporation (the "Company") and Light Hammer, LLC (the "Investor") have entered into an Amended and Restated 10% Convertible Debenture dated as of May 29, 2012, in the principal amount of $65,000.00 (the "Note").

 

A copy of the Note is attached hereto. You should familiarize yourself with your issuance and delivery obligations, as Transfer Agent, contained therein. The shares to be issued are to be registered in the names of the registered holder of the securities submitted for conversion or exercise.

 

You are hereby irrevocably authorized and instructed to reserve a sufficient number of shares of common stock ("Common Stock") of the Company (initially, 200,000,000 shares) for issuance upon full conversion of the Note in accordance with the terms thereof. The amount of Common Stock so reserved may be increased, from time to time, by written instructions of the Company and the Investor.

 

The ability to convert the Note in a timely manner is a material obligation of the Company pursuant to the Note. Your firm is hereby irrevocably authorized and instructed to issue shares of Common Stock of the Company (without any restrictive legend) to the Investor

 

(A) upon your receipt from the Investor of: (i) a notice of conversion ("Conversion Notice") executed by the Investor; and (ii) an opinion of counsel of the Investor, in form, substance and scope customary for opinions of counsel in comparable transactions (and satisfactory to the transfer agent), to the effect that the shares of Common Stock of the Company issued to the Investor pursuant to the Conversion Notice are not "restricted securities" as defined in Rule 144 and should be issued to the Investor without any restrictive legend; and (B) the number of shares to be issued is less than 4.99% of the total issued common stock of the Company.

 

The Company hereby requests that your firm act immediately and without delay with respect to the issuance of Common Stock pursuant to any Conversion Notices received from the Investor.

 

The Company shall indemnify you and your officers, directors, principals, partners, agents and representatives, and hold each of them harmless from and against any and all loss, liability, damage, claim or expense (including the reasonable fees and disbursements of its attorneys) incurred by or asserted against you or any of them arising out of or in connection the instructions set forth herein, the performance of your duties hereunder and otherwise in respect hereof, including the costs and expenses of defending yourself or themselves against any claim or liability hereunder, except that the Company shall not be liable hereunder
as to matters in respect of which it is determined that you have acted with gross negligence or in bad faith. You shall have no liability to the Company in respect to any action taken or any failure to act in respect of this if such action was taken or omitted to be taken in good faith, and you shall be entitled to rely in this regard on the advice of counsel.

 

  

3

  

 

The Board of Directors of the Company has approved the foregoing (irrevocable instructions) and does hereby extend the Company's irrevocable agreement to indemnify your firm for all loss, liability or expense in carrying out the authority and direction herein contained on the terms herein set forth.

 

The Company agrees that in the event that the Transfer Agent resigns as the Company's transfer agent, the Company shall engage a suitable replacement transfer agent that will agree to serve as transfer agent for the Company and be bound by the terms and conditions of these Irrevocable Instructions within five (5) business days.

 

The Investor is intended to be and are third party beneficiaries hereof, and no amendment or modification to the instructions set forth herein may be made without the consent of the Investor.

 

Very truly yours,

 

MEDICAL CARE TECHNOLOGIES INC.

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]